Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19.
作者信息
Gatto Lidia, Franceschi Enrico, Nunno Vincenzo Di, Brandes Alba Ariela
机构信息
Department of Medical Oncology, Azienda USL/IRCCS Institute of Neurological Sciences, Bologna, Italy.
出版信息
Immunotherapy. 2020 Oct;12(15):1111-1114. doi: 10.2217/imt-2020-0109. Epub 2020 Jun 29.
Abstract
摘要
相似文献
1
Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19.免疫检查点抑制剂对病毒感染和新冠肺炎的潜在保护及治疗作用。
Immunotherapy. 2020 Oct;12(15):1111-1114. doi: 10.2217/imt-2020-0109. Epub 2020 Jun 29.
2
Obesity, COVID-19 and immunotherapy: the complex relationship!肥胖、新冠病毒病与免疫疗法：复杂的关系！
Immunotherapy. 2020 Oct;12(15):1105-1109. doi: 10.2217/imt-2020-0178. Epub 2020 Jul 17.
3
Coronavirus Disease 2019 (COVID-19) and Immune-Engaging Cancer Treatment.2019冠状病毒病（COVID-19）与免疫参与性癌症治疗
JAMA Oncol. 2020 Oct 1;6(10):1529-1530. doi: 10.1001/jamaoncol.2020.2367.
4
COVID-19 and the newly rediscovered multidisciplinarity.新冠疫情与新发现的多学科交叉性
Immunotherapy. 2020 Oct;12(15):1101-1103. doi: 10.2217/imt-2020-0205. Epub 2020 Sep 21.
5
Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors.曾接触过免疫检查点抑制剂的癌症患者感染2019冠状病毒病（COVID-19）的临床结局
Cancer Commun (Lond). 2020 Aug;40(8):374-379. doi: 10.1002/cac2.12077. Epub 2020 Jul 15.
6
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era.免疫检查点抑制剂在 COVID-19 时代的癌症治疗中的应用。
Clin Cancer Res. 2020 Aug 15;26(16):4201-4205. doi: 10.1158/1078-0432.CCR-20-1657. Epub 2020 Jun 15.
7
Covid-19: Human challenge studies will see people purposefully infected with virus.新冠疫情：人体挑战试验将让人们故意感染病毒。
BMJ. 2020 Oct 22;371:m4101. doi: 10.1136/bmj.m4101.
8
[Implications of the COVID-19 pandemic for cancer in Spain].[新冠疫情对西班牙癌症的影响]
Med Clin (Barc). 2020 Sep 25;155(6):263-266. doi: 10.1016/j.medcli.2020.04.011. Epub 2020 May 8.
9
How to face cancer treatment in the COVID-19 era.在新冠疫情时代如何面对癌症治疗
Expert Rev Anticancer Ther. 2020 Jun;20(6):429-432. doi: 10.1080/14737140.2020.1766355. Epub 2020 May 18.
10
The allergist/immunologist, the Janus gatekeeper of inflammation, COVID-19 and beyond.过敏症专科医生/免疫学家，炎症、新冠疫情及其他领域的双面守门人。
Allergy Asthma Proc. 2020 Nov 1;41(6):395-396. doi: 10.2500/aap.2020.41.200084.
引用本文的文献
1
Safety of immune checkpoint inhibitors in cancer patients with COVID-19: A review.免疫检查点抑制剂在新冠肺炎癌症患者中的安全性：综述
Medicine (Baltimore). 2025 Aug 8;104(32):e43579. doi: 10.1097/MD.0000000000043579.
2
Predicting survival in patients with SARS-CoV-2 based on cytokines and soluble immune checkpoint regulators.基于细胞因子和可溶性免疫检查点调节因子预测新型冠状病毒2型患者的生存率
Front Cell Infect Microbiol. 2024 Nov 25;14:1397297. doi: 10.3389/fcimb.2024.1397297. eCollection 2024.
3
In Silico Exploration of CD200 as a Therapeutic Target for COVID-19.CD200作为COVID-19治疗靶点的计算机模拟研究
Microorganisms. 2024 Jun 12;12(6):1185. doi: 10.3390/microorganisms12061185.
4
Association of immune checkpoint inhibitors with SARS-CoV-2 infection rate and prognosis in patients with solid tumors: a systematic review and meta-analysis.免疫检查点抑制剂与实体瘤患者 SARS-CoV-2 感染率和预后的关系：系统评价和荟萃分析。
Front Immunol. 2024 Jun 3;15:1259112. doi: 10.3389/fimmu.2024.1259112. eCollection 2024.
5
SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors.癌症患者接受免疫检查点抑制剂治疗时的 SARS-CoV-2 感染和 COVID-19 疫苗接种。
Cell Death Dis. 2023 Jun 30;14(6):390. doi: 10.1038/s41419-023-05922-w.
6
Prognostic impacts of soluble immune checkpoint regulators and cytokines in patients with SARS-CoV-2 infection.可溶性免疫检查点调节剂和细胞因子对 SARS-CoV-2 感染患者预后的影响。
Front Immunol. 2022 Aug 15;13:903419. doi: 10.3389/fimmu.2022.903419. eCollection 2022.
7
Clinical course of COVID-19 infection in a melanoma patient treated with nivolumab and bempegaldesleukin: a case report.纳武利尤单抗和贝林妥欧单抗治疗黑素瘤患者的 COVID-19 感染临床过程：病例报告。
Immunotherapy. 2022 Sep;14(13):1015-1020. doi: 10.2217/imt-2021-0331. Epub 2022 Jul 19.
8
CD8 T Cells in SARS-CoV-2 Induced Disease and Cancer-Clinical Perspectives.CD8 T 细胞在 SARS-CoV-2 诱导的疾病和癌症中的临床观察。
Front Immunol. 2022 Apr 1;13:864298. doi: 10.3389/fimmu.2022.864298. eCollection 2022.
9
Challenges posed by COVID-19 in cancer patients: A narrative review.COVID-19 对癌症患者带来的挑战：一篇叙述性综述。
Cancer Med. 2022 Feb;11(4):1119-1135. doi: 10.1002/cam4.4519. Epub 2021 Dec 23.
10
Immunological Approaches to the Treatment of New Coronavirus Infection (Review).免疫治疗新型冠状病毒感染的方法（综述）。
Sovrem Tekhnologii Med. 2021;13(3):81-99. doi: 10.17691/stm2021.13.3.09. Epub 2021 Jun 28.
本文引用的文献
1
COVID-19 and lung cancer: risks, mechanisms and treatment interactions.新型冠状病毒肺炎与肺癌：风险、机制和治疗相互作用。
J Immunother Cancer. 2020 May;8(1). doi: 10.1136/jitc-2020-000892.
2
How we treat patients with lung cancer during the SARS-CoV-2 pandemic: .在 SARS-CoV-2 大流行期间我们如何治疗肺癌患者：。
ESMO Open. 2020 Apr;5(2):e000765. doi: 10.1136/esmoopen-2020-000765.
3
Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic.癌症、COVID-19 和预防原则：在全球大流行期间优先考虑治疗。
Nat Rev Clin Oncol. 2020 May;17(5):268-270. doi: 10.1038/s41571-020-0362-6.
4
Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspective.在意大利 2019 冠状病毒病（COVID-19）传播期间的癌症护理：青年肿瘤学家的观点。
ESMO Open. 2020 Mar;5(2). doi: 10.1136/esmoopen-2020-000759.
5
Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors.关于新型冠状病毒肺炎和使用免疫检查点抑制剂进行抗癌治疗的争议。
Immunotherapy. 2020 Apr;12(5):269-273. doi: 10.2217/imt-2020-0067. Epub 2020 Mar 26.
6
COVID-19 infection: the perspectives on immune responses.新型冠状病毒肺炎感染：免疫反应的观点
Cell Death Differ. 2020 May;27(5):1451-1454. doi: 10.1038/s41418-020-0530-3. Epub 2020 Mar 23.
7
TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.COVID-19 细胞因子风暴中的 TH17 反应：JAK2 抑制剂 Fedratinib 的一个新靶点。
J Microbiol Immunol Infect. 2020 Jun;53(3):368-370. doi: 10.1016/j.jmii.2020.03.005. Epub 2020 Mar 11.
8
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
9
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.新型冠状病毒肺炎（SARS-CoV-2）感染的癌症患者：一项中国全国性分析。
Lancet Oncol. 2020 Mar;21(3):335-337. doi: 10.1016/S1470-2045(20)30096-6. Epub 2020 Feb 14.
10
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
Zotero 插件